2025 China Autologous Cell Therapy Market Revenue Opportunities Report
Description
The 2025 China Autologous Cell Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autologous cell therapy market in China are JW Therapeutics, Fosun Kite Biotechnology, Juventas Cell Therapy Ltd., and TCRCure Biopharma. JW Therapeutics, a joint venture between Juno Therapeutics and WuXi AppTec, focuses on developing, manufacturing, and commercializing breakthrough CAR-T therapies targeting hematological cancers, exemplified by its anti-CD19 product Relma-cel. Fosun Kite, a partnership between Fosun Pharmaceutical Group and Gilead Sciences’ Kite Pharma, has established a significant presence in China with a large commercial manufacturing facility for CAR-T therapies, leveraging its global expertise.
Juventas Cell Therapy, based in Tianjin, develops CD19 CAR-T therapies for blood cancers, collaborating with CASI Pharmaceuticals to commercialize these treatments domestically. TCRCure Biopharma operates a leading ""One-Stop Shop"" platform across the U.S. and China, focusing on solid tumor CAR-T and TCR-T therapies, with multiple pipelines and clinical collaborations to advance cell therapy applications in China. These companies contribute significantly to China's rapid growth in autologous cell therapy, supported by investment, government backing, and clinical trial activity.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autologous cell therapy market in China are JW Therapeutics, Fosun Kite Biotechnology, Juventas Cell Therapy Ltd., and TCRCure Biopharma. JW Therapeutics, a joint venture between Juno Therapeutics and WuXi AppTec, focuses on developing, manufacturing, and commercializing breakthrough CAR-T therapies targeting hematological cancers, exemplified by its anti-CD19 product Relma-cel. Fosun Kite, a partnership between Fosun Pharmaceutical Group and Gilead Sciences’ Kite Pharma, has established a significant presence in China with a large commercial manufacturing facility for CAR-T therapies, leveraging its global expertise.
Juventas Cell Therapy, based in Tianjin, develops CD19 CAR-T therapies for blood cancers, collaborating with CASI Pharmaceuticals to commercialize these treatments domestically. TCRCure Biopharma operates a leading ""One-Stop Shop"" platform across the U.S. and China, focusing on solid tumor CAR-T and TCR-T therapies, with multiple pipelines and clinical collaborations to advance cell therapy applications in China. These companies contribute significantly to China's rapid growth in autologous cell therapy, supported by investment, government backing, and clinical trial activity.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
